Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy

to related objects

Abstract: Immune checkpoint inhibitor (ICI) restores an efficient antitumor T cell response against tumor cells fostering durable responses that can persist even after the treatment. However, these treatment effects can manifest as an unusual pattern of disease progression, pseudo-progression, or hyper-progression. Differentiating hyper progressive disease (HPD) from pseudo-progression has significant clinical implications and further decision-making for the patient on ICI. HPD is a dramatic acceleration of the rate of tumor progression with the advent of immunotherapeutic agents causing detrimental effects on the disease outcome.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy ; volume:43 ; number:02 ; year:2022 ; pages:185-188
Indian journal of medical & paediatric oncology ; 43, Heft 02 (2022), 185-188

Contributor
Jain, Arpit
Koyyala, Venkata Pradeep Babu
Narayan, Satya
Soni, Satyajeet
Redhu, Pallavi
Jaju, Akanksha

DOI
10.1055/s-0042-1743505
URN
urn:nbn:de:101:1-2022061610114992500866
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Jain, Arpit
  • Koyyala, Venkata Pradeep Babu
  • Narayan, Satya
  • Soni, Satyajeet
  • Redhu, Pallavi
  • Jaju, Akanksha

Other Objects (12)

Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors

Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature

Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy

Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

Neurosarcoidosis following Immune Checkpoint Inhibition

Neurosarcoidosis following Immune Checkpoint Inhibition

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Immune checkpoint analysis in lip cancer

Hochschulschrift

Immune checkpoint analysis in lip cancer

Immune checkpoint inhibitor-related acral vasculitis

Immune checkpoint inhibitor-related acral vasculitis

Immune checkpoint blockade in ovarian cancer

Immune checkpoint blockade in ovarian cancer

Related objects